Literature DB >> 21302967

Blockade of IL-6 secretion pathway by the sesquiterpenoid atractylenolide III.

Tae-Hee Kang1, Na-Ra Han, Hyung-Min Kim, Hyun-Ja Jeong.   

Abstract

Atractylenolide III (1) is the major bioactive component of Atractylodes lancea. The aim of this study was to analyze the effect on the regulation of interleukin (IL)-6 secretion pathway caused by 1. This sesquiterpenoid inhibited the secretion and expression of IL-6 in phorbol 12-myristate 13-acetate- and calcium ionophore A23187-stimulated human mast cells (HMC)-1. In addition, 1 inhibited histamine release in stimulated HMC-1 cells. In stimulated HMC-1 cells, 1 suppressed activation of p38 mitogen-activated protein kinase, C-Jun-N-terminal protein kinase, and nuclear factor-κB. In addition, 1 suppressed the activation of caspase-1 and the expression of receptor interacting protein-2. These results provide new insights that atractylenolide III (1) may control immunological reactions by regulating the cellular functions of IL-6 in mast cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21302967     DOI: 10.1021/np100686a

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  8 in total

1.  Chemical and ecological evaluation of a genuine Chinese medicine: Atractylodes macrocephala Koidz.

Authors:  Jue Zhou; Fan Qu; Yongping Yu
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-06-01

2.  Atractylenolide III Attenuates Muscle Wasting in Chronic Kidney Disease via the Oxidative Stress-Mediated PI3K/AKT/mTOR Pathway.

Authors:  Mingqing Wang; Rong Hu; Yanjing Wang; Lingyu Liu; Haiyan You; Jiaxing Zhang; Xiaohui Wu; Tingting Pei; Fujing Wang; Lu Lu; Wei Xiao; Lianbo Wei
Journal:  Oxid Med Cell Longev       Date:  2019-04-18       Impact factor: 6.543

3.  Mannose-Modified Multi-Walled Carbon Nanotubes as a Delivery Nanovector Optimizing the Antigen Presentation of Dendritic Cells.

Authors:  Zhipeng Dong; Qiyan Wang; Ming Huo; Nanxia Zhang; Bingxia Li; Hongmei Li; Yisong Xu; Meng Chen; Hao Hong; Yue Wang
Journal:  ChemistryOpen       Date:  2019-07-12       Impact factor: 2.911

4.  Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.

Authors:  Qian Li; Jia-Xin Tan; Yong He; Fang Bai; Shi-Wei Li; Yi-Wen Hou; Long-Shan Ji; Ya-Ting Gao; Xin Zhang; Zhen-Hua Zhou; Zhuo Yu; Miao Fang; Yue-Qiu Gao; Man Li
Journal:  Int J Biol Sci       Date:  2022-01-31       Impact factor: 6.580

5.  Atractylenolide III inhibits epithelial‑mesenchymal transition in small intestine epithelial cells by activating the AMPK signaling pathway.

Authors:  Mingjin Huang; Wenwen Jiang; Chunli Luo; Min Yang; Yan Ren
Journal:  Mol Med Rep       Date:  2022-01-28       Impact factor: 3.423

6.  Atractylenolide III Improves Mitochondrial Function and Protects Against Ulcerative Colitis by Activating AMPK/SIRT1/PGC-1α.

Authors:  Jieru Han; Wenhao Li; Guangyu Shi; Yunlei Huang; Xutao Sun; Na Sun; Deyou Jiang
Journal:  Mediators Inflamm       Date:  2022-04-08       Impact factor: 4.529

7.  Atractylenolide III Attenuates Apoptosis in H9c2 Cells by Inhibiting Endoplasmic Reticulum Stress through the GRP78/PERK/CHOP Signaling Pathway.

Authors:  Meng-Yu Zuo; Tong-Juan Tang; Xiang Wang; Jin-Fan Gu; Liang Wang; Jian Chen; Juan Yao; Xiang-Yang Li; Peng Zhou; Jin-Ling Huang
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-14       Impact factor: 2.650

Review 8.  Atractylenolides (I, II, and III): a review of their pharmacology and pharmacokinetics.

Authors:  Mao Deng; Huijuan Chen; Jiaying Long; Jiawen Song; Long Xie; Xiaofang Li
Journal:  Arch Pharm Res       Date:  2021-07-16       Impact factor: 4.946

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.